Most patients survive acute myocardial infarction (MI). Yet this encouraging development
has certain drawbacks: heart failure (HF) prevalence is increasing and patients affected tend …

Aims The aim of the present paper was to provide an up‐to‐date view on epidemiology and
risk factors of heart failure (HF) development after myocardial infarction. Methods and results …

Background In patients with acute myocardial infarction (MI), therapies that could further
reduce the risk of adverse cardiovascular and metabolic outcomes are needed. Methods In …

Background Patients with acute myocardial infarction (MI) are at risk for developing heart
failure (HF) and subsequently are at an increased risk of mortality. Sodium-glucose …

Background Diabetes and elevated blood glucose have been associated with increased risk
of atrial fibrillation in a number of epidemiological studies, however, the findings have not …

Background Therapies that could further prevent the development of heart failure (HF) and
other cardiovascular and metabolic events in patients with recent myocardial infarction (MI) …

Background: Patients with left ventricular (LV) systolic dysfunction after myocardial infarction
are at a high risk of developing heart failure. The addition of neprilysin inhibition to renin …

Aims Empagliflozin has been shown to reduce the risk of adverse cardiovascular outcomes
in patients with type 2 diabetes and in those with heart failure. The impact of empagliflozin in …

Background Patients have an estimated mortality of 15–20% within the first year following
myocardial infarction and one in four patients who survive myocardial infarction will develop …

Abstract Background and Aim The strength of the association between diabetes and risk of
heart failure has differed between previous studies and the available studies have not been …